Biological activity of a mouse-human chimeric immunoglobulin G2 antibody to Cryptococcus neoformans polysaccharide

Clinical and Diagnostic Laboratory Immunology

Volumn 9, Issue 1, 2002, Pages 201-204

  Kwon, Katherine Westin ^a   Lendvai, Nikoletta ^a   Morrison, Sherie ^a   Trinh, K Ryan ^a   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G2;

ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ARTICLE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FUNGUS IDENTIFICATION; INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, FUNGAL; ANTIBODIES, MONOCLONAL; CRYPTOCOCCUS NEOFORMANS; HUMANS; IMMUNOGLOBULIN G; MICE; POLYSACCHARIDES; RECOMBINANT FUSION PROTEINS;

EID: 0036148182     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.9.1.201-204.2002     Document Type: Article

References (22)

1. Cryptococcosis: The case for immunotherapy
2. Passive antibody therapies: Progress and continuing challenges
3. Characterization of a murine monoclonal antibody to Cryptocococcus neoformans polysaccharide that is a candidate for human therapeutic studies
4. Antibodies elicited by a Cryptococcus neoformans glucuronoxylomannan-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection
5. Monoclonal antibody ELISAs for cryptococcal polysaccharide
6. Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans
7. Prevalence in Cryptococcus neoformans strains of a polysaccharide epitope which can elicit protective antibodies
8. Role of heavy chain constant domains in antibody-antigen interaction
9. H chain C domains influence the strength of binding of IgG for streptococcal group A carbohydrate
10. Estimation of the prevalence of cryptococcal infection among HIV infected individuals in New York City
11. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis
12. Antibody mediated toxicity in Cryptococcus neoformans infection: Mechanism and relationship to antibody isotype
13. Mechanism for the isotype dependence of antibody-mediated toxicity in Cryptococcus neoformans infected mice
14. Protective murine monoclonal antibodies to Cryptococcus neoformans
15. J774 murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins
16. Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis
17. Persistence of the initial infection in recurrent cryptococcal meningitis
18. Antibody-mediated effects against Cryptococcus neoformans: Evidence for interdependency and collaboration between humoral and cellular immunity
19. Isotype switching from IgG3 to IgG1 converts a non-protective murine antibody to C. neoformans into a protective antibody
20. Isotype switching increases antibody protective efficacy to Crytococcus neoformans infection in mice
21. Mouse-human immunoglobulin G1 chimeric antibodies with activity against Cryptococcus neoformans
22. Antifungal activity of a human antiglucuronoxylomannan antibody